Major study tracks Real-World impact of rare muscle disease treatment
NCT ID NCT03555578
Summary
This study aims to monitor the long-term safety and effectiveness of an approved injection treatment for spinal and bulbar muscular atrophy (SBMA) in real-world medical settings. It will observe about 300 patients in Japan who are already receiving the treatment, tracking their health outcomes for up to eight years. The main goal is to collect information on side effects and how well the treatment helps control the disease over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL AND BULBAR MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda Selected Site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.